Edelman A S, Xue B, Galton J E, Sanchez P, Thorbecke G J
J Immunol. 1985 Sep;135(3):2213-9.
Primary carcinogen-induced (7,12-dimethyl-benz[a]anthracene; DMBA) tumor-bearing SC chickens (B2/B2) frequently showed antibodies in their sera which reacted with cells from their autochthonous tumors, chicken embryo fibroblasts (CEF), tumor cells from some transplantable tumor lines, and from approximately 10% of other primary tumors. Similar results were obtained by ELISA on glutaraldehyde-fixed cells and by immunofluorescence on viable cells. The serum antibody reactivity could be removed by absorption with CEF but not with non-cross-reacting primary tumor cells or a variety of normal tissues. Although sera from normal chickens never showed significant reactivity, a high percentage of sera from chickens that had been injected with DMBA but failed to develop detectable tumors showed antibody activity to a transplantable DMBA-induced tumor and to CEF. On the basis of previously established cross-reactivity patterns in protective immunity to transplantable carcinogen-induced fibrosarcomas, attempts were made to protect against chemical carcinogenesis by prior immunization with selected DMBA-induced transplantable tumors. Tumor-immune chickens showed a significant decrease in the development of tumors during the first 3 mo after injection of DMBA (p = 0.001) or methylcholanthrene (p = 0.033) when compared to controls. This resistance to tumor induction in immune chickens was correlated to the degree of tumor immunity to the immunizing tumor present 1 mo after carcinogen injection (p = 0.046). There was, however, no detectable difference in the incidence of tumors arising later than 3 mo after carcinogen injection. The reduction in tumor incidence in immune as compared to control chickens at 5 mo was therefore less striking than the reduction seen at 3 mo. Immunization with CEF and adjuvants or with adjuvants alone afforded no protection to tumor induction.
原发性致癌物诱导(7,12 - 二甲基苯并[a]蒽;DMBA)的荷瘤SC鸡(B2/B2)血清中常出现抗体,这些抗体能与自身原发性肿瘤细胞、鸡胚成纤维细胞(CEF)、一些可移植肿瘤系的肿瘤细胞以及约10%的其他原发性肿瘤细胞发生反应。通过酶联免疫吸附测定(ELISA)检测戊二醛固定细胞以及通过免疫荧光检测活细胞,均得到类似结果。血清抗体反应性可通过与CEF吸收去除,但不能通过与非交叉反应的原发性肿瘤细胞或多种正常组织吸收去除。虽然正常鸡的血清从未显示出明显反应性,但注射DMBA但未形成可检测肿瘤的鸡,其血清中有很高比例对可移植的DMBA诱导肿瘤和CEF显示出抗体活性。基于先前在对可移植致癌物诱导纤维肉瘤的保护性免疫中建立的交叉反应模式,尝试通过预先用选定的DMBA诱导可移植肿瘤免疫来预防化学致癌作用。与对照组相比,肿瘤免疫鸡在注射DMBA(p = 0.001)或甲基胆蒽(p = 0.033)后的前3个月内肿瘤发生显著减少。免疫鸡对肿瘤诱导的这种抗性与致癌物注射1个月后对免疫肿瘤的肿瘤免疫程度相关(p = 0.046)。然而,在致癌物注射3个月后出现的肿瘤发生率没有可检测到的差异。因此,与对照鸡相比,免疫鸡在5个月时肿瘤发生率的降低不如在3个月时明显。用CEF和佐剂或仅用佐剂免疫对肿瘤诱导没有保护作用。